These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 20695724)

  • 21. Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA).
    Whitehouse PA; Knight LA; Di Nicolantonio F; Mercer SJ; Sharma S; Cree IA;
    Anticancer Drugs; 2003 Jun; 14(5):369-75. PubMed ID: 12782944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors associated with success of the extreme drug resistance assay in primary breast cancer specimens.
    Ellis RJ; Fabian CJ; Kimler BF; Tawfik O; Mayo MS; Decelis CR; Jewell WR; Connor C; Modrell C; Praeger M; McGinness M; Mehta R; Fruehauf JP
    Breast Cancer Res Treat; 2002 Jan; 71(2):95-102. PubMed ID: 11881914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deciphering cellular states of innate tumor drug responses.
    Graudens E; Boulanger V; Mollard C; Mariage-Samson R; Barlet X; Grémy G; Couillault C; Lajémi M; Piatier-Tonneau D; Zaborski P; Eveno E; Auffray C; Imbeaud S
    Genome Biol; 2006; 7(3):R19. PubMed ID: 16542501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial with Brequinar (DUP-785, NSC 368390) in patients with metastatic colorectal cancer: a study of the Early Clinical Trials Group of the EORTC.
    Dodion PF; Wagener T; Stoter G; Drozd A; Lev LM; Skovsgaard T; Renard J; Cavalli F
    Ann Oncol; 1990; 1(1):79-80. PubMed ID: 2078489
    [No Abstract]   [Full Text] [Related]  

  • 25. Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept.
    Morand du Puch CB; Vanderstraete M; Giraud S; Lautrette C; Christou N; Mathonnet M
    Theranostics; 2021; 11(19):9538-9556. PubMed ID: 34646385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumour-Derived Cell Lines and Their Potential for Therapy Prediction in Patients with Metastatic Colorectal Cancer.
    Wagner S; Beger NT; Matschos S; Szymanski A; Przybylla R; Bürtin F; Prall F; Linnebacher M; Mullins CS
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical value of an adenosine triphosphate-based chemotherapy response assay in resectable stage III colorectal cancer.
    Kim CD; Kim SH; Jung SH; Kim JH
    Ann Surg Treat Res; 2019 Aug; 97(2):93-102. PubMed ID: 31384612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Precision Medicine for CRC Patients in the Veteran Population: State-of-the-Art, Challenges and Research Directions.
    Mohapatra SS; Batra SK; Bharadwaj S; Bouvet M; Cosman B; Goel A; Jogunoori W; Kelley MJ; Mishra L; Mishra B; Mohapatra S; Patel B; Pisegna JR; Raufman JP; Rao S; Roy H; Scheuner M; Singh S; Vidyarthi G; White J
    Dig Dis Sci; 2018 May; 63(5):1123-1138. PubMed ID: 29572615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells.
    Pedraz-Cuesta E; Christensen S; Jensen AA; Jensen NF; Bunch L; Romer MU; Brünner N; Stenvang J; Pedersen SF
    BMC Cancer; 2015 May; 15():411. PubMed ID: 25981639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent applications of chemosensitivity tests for colorectal cancer treatment.
    Yoon YS; Kim JC
    World J Gastroenterol; 2014 Nov; 20(44):16398-408. PubMed ID: 25469008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of individual response to anticancer therapy: historical and future perspectives.
    Unger FT; Witte I; David KA
    Cell Mol Life Sci; 2015 Feb; 72(4):729-57. PubMed ID: 25387856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative label-free LC-MS/MS analysis of colorectal adenocarcinoma and metastatic cells treated with 5-fluorouracil.
    Bauer KM; Lambert PA; Hummon AB
    Proteomics; 2012 Jun; 12(12):1928-37. PubMed ID: 22623418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is there a third-line therapy for metastatic colorectal cancer?
    Grothey A
    Semin Oncol; 2006 Dec; 33(6 Suppl 11):S36-8. PubMed ID: 17178284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro drug responses in primary and metastatic colorectal cancers.
    Mechetner E; Brünner N; Parker RJ
    Scand J Gastroenterol; 2011 Jan; 46(1):70-8. PubMed ID: 20695724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.
    Viel E; Demarchi MF; Chaigneau L; Nguyen T; Legat C; Stein U; Thiery-Vuillemin A; Limat S; Pivot X; Borg C
    Am J Clin Oncol; 2008 Feb; 31(1):89-94. PubMed ID: 18376234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.